InvestorsHub Logo
Followers 34
Posts 2049
Boards Moderated 0
Alias Born 12/03/2013

Re: None

Tuesday, 11/25/2014 7:26:16 AM

Tuesday, November 25, 2014 7:26:16 AM

Post# of 48316
OK guys, so this is obviously great news. It's as myself and many suspected, not a partnership with upfront cash but rather Merck supplying the drug. Obviously if the results from this trial are what we think they are, a more significant partnership with Merck will likely follow. I think back to our friend Pazzo telling us that Punit told him something to the effect that "more trials were needed before a partnership." That makes sense to me now. Punit probably knew all along that Merck was willing to provide the drug for free but they wanted to see results from a trial before committing to a partnership with financial incentives. The positive of this, however, is ONCS will have more leverage if the results are a home run. In other words they won't be bound by possibly weaker financial terms that may have been negotiated at this point. The bad news is that we'll need to raise cash in the near future, as we all knew would be the case without a major cash influx from a partnership.

My only other comment on this is that I sure wish the PR made a bigger deal over the collaboration with Merck. I'm sure there are legal reasons for leaving Merck out of the headline, but I sure would have liked to see more of an emphasis on the partnering/collaborating with Merck, rather than UCSF. But again, obviously this is great news.